Simulations Plus – a leading supplier of modeling and simulation software as well as services in the field of pharmaceutical safety and effectiveness, announced the conclusion of a research cooperation agreement with our Institute.
The aim of the cooperation is to design new compounds for the RORγ / RORγT nuclear receptors using the latest artificial intelligence (AI) and machine learning (ML) technology on the ADMET Predictor® software platform. Both Simulations Plus and IBM PAN will make significant intellectual contributions to research, and the intellectual property resulting from the collaboration will be the basis for further development opportunities.